PDCD1 and neoplasm: Therefore, additional multicenter, randomized controlled prospective studies are needed, specifically in patients with advanced HCC who receive a PD-1 inhibitor in combination with lenvatinib as the first-line regimen, to evaluate the predictive ability of tumor LS and the underlying mechanisms of LS-associated disease progression.